Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids?

Carol A. Derby, Kate L. Lapane, Anne Lamont Hume, Marilyn McFarland Barbour, Richard A. Carleton

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We examined the relation between current use of antihypertensive medications and lipid levels in relation to smoking status. We used data from cross-sectional random sample surveys conducted between 1981 and 1993 in two southeastern New England communities. The analysis included 3,027 normotensive, 1,416 untreated hypertensive, and 1,174 treated hypertensive survey respondents between 40 and 64 years of age. After adjustment for body mass index, diabetes mellitus, alcohol use, use of medications with adverse lipid effects, age, and sex, the estimated mean high-density-lipoprotein- cholesterol level among hypertensives using beta-blockers [44.6 mg per dl; 95% confidence interval (CI) = 43.l-46.1] was lower than that for either untreated hypertensives (48.5 mg per dl; 95% CI = 47.8-49.2) or normotensives (47.1 mg per dl; 95% CI = 46.6-47.6). This pattern was similar among smokers and nonsmokers. Smokers treated with beta-blockers, however, had particularly low levels of high-density-lipoprotein-cholesterol (43.4 mg per dl; 95% CI = 40.7-46.l), compared with non-smokers using beta-blockers (45.8 mg per dl; 95% CI = 44.247.3). Low levels of high-density-lipoprotein-cholesterol may increase the risk of coronary heart disease among smokers using beta- blockers.

Original languageEnglish (US)
Pages (from-to)48-54
Number of pages7
JournalEpidemiology
Volume8
Issue number1
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Antihypertensive Agents
Smoking
Confidence Intervals
Lipids
HDL Cholesterol
Therapeutics
New England
Coronary Disease
Diabetes Mellitus
Body Mass Index
Alcohols
Surveys and Questionnaires

Keywords

  • antihypertensives
  • high-density- lipoproteins
  • lipids
  • population survey
  • smoking

ASJC Scopus subject areas

  • Epidemiology

Cite this

Derby, C. A., Lapane, K. L., Hume, A. L., Barbour, M. M., & Carleton, R. A. (1997). Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids? Epidemiology, 8(1), 48-54.

Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids? / Derby, Carol A.; Lapane, Kate L.; Hume, Anne Lamont; Barbour, Marilyn McFarland; Carleton, Richard A.

In: Epidemiology, Vol. 8, No. 1, 01.1997, p. 48-54.

Research output: Contribution to journalArticle

Derby, CA, Lapane, KL, Hume, AL, Barbour, MM & Carleton, RA 1997, 'Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids?', Epidemiology, vol. 8, no. 1, pp. 48-54.
Derby, Carol A. ; Lapane, Kate L. ; Hume, Anne Lamont ; Barbour, Marilyn McFarland ; Carleton, Richard A. / Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids?. In: Epidemiology. 1997 ; Vol. 8, No. 1. pp. 48-54.
@article{c327fd930bd14a5a927da87a2e00ee9c,
title = "Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids?",
abstract = "We examined the relation between current use of antihypertensive medications and lipid levels in relation to smoking status. We used data from cross-sectional random sample surveys conducted between 1981 and 1993 in two southeastern New England communities. The analysis included 3,027 normotensive, 1,416 untreated hypertensive, and 1,174 treated hypertensive survey respondents between 40 and 64 years of age. After adjustment for body mass index, diabetes mellitus, alcohol use, use of medications with adverse lipid effects, age, and sex, the estimated mean high-density-lipoprotein- cholesterol level among hypertensives using beta-blockers [44.6 mg per dl; 95{\%} confidence interval (CI) = 43.l-46.1] was lower than that for either untreated hypertensives (48.5 mg per dl; 95{\%} CI = 47.8-49.2) or normotensives (47.1 mg per dl; 95{\%} CI = 46.6-47.6). This pattern was similar among smokers and nonsmokers. Smokers treated with beta-blockers, however, had particularly low levels of high-density-lipoprotein-cholesterol (43.4 mg per dl; 95{\%} CI = 40.7-46.l), compared with non-smokers using beta-blockers (45.8 mg per dl; 95{\%} CI = 44.247.3). Low levels of high-density-lipoprotein-cholesterol may increase the risk of coronary heart disease among smokers using beta- blockers.",
keywords = "antihypertensives, high-density- lipoproteins, lipids, population survey, smoking",
author = "Derby, {Carol A.} and Lapane, {Kate L.} and Hume, {Anne Lamont} and Barbour, {Marilyn McFarland} and Carleton, {Richard A.}",
year = "1997",
month = "1",
language = "English (US)",
volume = "8",
pages = "48--54",
journal = "Epidemiology",
issn = "1044-3983",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Is cigarette smoking an effect modifier of the relation between antihypertensive therapy and blood lipids?

AU - Derby, Carol A.

AU - Lapane, Kate L.

AU - Hume, Anne Lamont

AU - Barbour, Marilyn McFarland

AU - Carleton, Richard A.

PY - 1997/1

Y1 - 1997/1

N2 - We examined the relation between current use of antihypertensive medications and lipid levels in relation to smoking status. We used data from cross-sectional random sample surveys conducted between 1981 and 1993 in two southeastern New England communities. The analysis included 3,027 normotensive, 1,416 untreated hypertensive, and 1,174 treated hypertensive survey respondents between 40 and 64 years of age. After adjustment for body mass index, diabetes mellitus, alcohol use, use of medications with adverse lipid effects, age, and sex, the estimated mean high-density-lipoprotein- cholesterol level among hypertensives using beta-blockers [44.6 mg per dl; 95% confidence interval (CI) = 43.l-46.1] was lower than that for either untreated hypertensives (48.5 mg per dl; 95% CI = 47.8-49.2) or normotensives (47.1 mg per dl; 95% CI = 46.6-47.6). This pattern was similar among smokers and nonsmokers. Smokers treated with beta-blockers, however, had particularly low levels of high-density-lipoprotein-cholesterol (43.4 mg per dl; 95% CI = 40.7-46.l), compared with non-smokers using beta-blockers (45.8 mg per dl; 95% CI = 44.247.3). Low levels of high-density-lipoprotein-cholesterol may increase the risk of coronary heart disease among smokers using beta- blockers.

AB - We examined the relation between current use of antihypertensive medications and lipid levels in relation to smoking status. We used data from cross-sectional random sample surveys conducted between 1981 and 1993 in two southeastern New England communities. The analysis included 3,027 normotensive, 1,416 untreated hypertensive, and 1,174 treated hypertensive survey respondents between 40 and 64 years of age. After adjustment for body mass index, diabetes mellitus, alcohol use, use of medications with adverse lipid effects, age, and sex, the estimated mean high-density-lipoprotein- cholesterol level among hypertensives using beta-blockers [44.6 mg per dl; 95% confidence interval (CI) = 43.l-46.1] was lower than that for either untreated hypertensives (48.5 mg per dl; 95% CI = 47.8-49.2) or normotensives (47.1 mg per dl; 95% CI = 46.6-47.6). This pattern was similar among smokers and nonsmokers. Smokers treated with beta-blockers, however, had particularly low levels of high-density-lipoprotein-cholesterol (43.4 mg per dl; 95% CI = 40.7-46.l), compared with non-smokers using beta-blockers (45.8 mg per dl; 95% CI = 44.247.3). Low levels of high-density-lipoprotein-cholesterol may increase the risk of coronary heart disease among smokers using beta- blockers.

KW - antihypertensives

KW - high-density- lipoproteins

KW - lipids

KW - population survey

KW - smoking

UR - http://www.scopus.com/inward/record.url?scp=0031021883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031021883&partnerID=8YFLogxK

M3 - Article

C2 - 9116095

AN - SCOPUS:0031021883

VL - 8

SP - 48

EP - 54

JO - Epidemiology

JF - Epidemiology

SN - 1044-3983

IS - 1

ER -